GRI Bio is developing an oral therapy for IPF, targeting inflammation earlier in the disease process with a large proprietary pipeline.
Source Post
The creator discusses the potential of small healthcare and biotech companies, specifically highlighting GR...
Andy InvestsNew
The creator discusses the potential of small healthcare and biotech companies, specifically highlighting GRI Bio Inc. as a sponsored feature. The video outlines the company's focus on treating idiopathic pulmonary fibrosis (IPF) and its proprietary pipeline of over 500 compounds.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.